CTOs on the Move

Visus Therapeutics

www.visustx.com

 
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOLâ„¢), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
  • Number of Employees: 25-100
  • Annual Revenue: $500M-1 Billion
  • www.visustx.com
  • 2 Nickerson Street Suite 101
    Seattle, WA USA 98109
  • Phone: 800.281.4536

Executives

Name Title Contact Details

Funding

Visus Therapeutics raised $36M on 03/09/2021

Similar Companies

ParaPRO

ParaPRO is a Carmel, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QCL Quality Compliance Laboratories Inc

QCL Quality Compliance Laboratories Inc is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oxis International

Oxis International, Inc. has formed and provided initial financing to support the activities of its wholly owned subsidiary, Oxis Biotech, Inc. The parent company, Oxis International is engaged in the research, development and sale of products to counteract oxidative stress and inflammation. Oxis Biotech is focused on the acquisition of cannabis related intellectual properties and commercialization of therapies developed from the intellectual properties to treat certain diseases.

PharmMD

At PharmMD, we believe every patient deserves personalized attention, the best information available, and reliable guidance from medical professionals to live a healthier life. This deeply held conviction guided our founder Fred McWhorter, an old-fashioned pharmacist who devoted more than 50 years to his passion of bringing health and healing to his customers–not simply selling medicine. Recognizing the value of emerging technology, he envisioned building a real-time information bridge between pharmacists (Pharm) and physicians (MD) to significantly improve patient treatment. Following Fred’s untimely death in 2005, his brother Clayton McWhorter, a veteran healthcare pioneer, brought Fred’s dream to fruition. In 2006, Clayton teamed with entrepreneur Samuel “Bo” Bartholomew to establish PharmMD in Nashville, TN. With the arrival of successful healthcare executive Robert Yeager as CEO in 2013, PharmMD pressed to the forefront in Medicare Part D Star Ratings improvement, as well as Medication Therapy Management (MTM) programs. Today PharmMD remains a leader in quality improvement and a healthcare industry innovator, delivering fast and effective solutions to CMS-regulated health plans and employer groups. Our pioneering technology, proprietary protocols and personalized patient profiles, combined with our outcomes-driven reporting, provide a catalyst for effective medication decisions; ultimately upholding Fred’s vision for improving lives. We exist to create a healthier world through the most effective use of the right medication.

Amedra Pharmaceuticals

Amedra Pharmaceuticals is a Middlesex, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.